SUMO3, human recombinant, BioVision

Supplier: BioVision

4943-100 4943-1000
10007-352EA 203.61 USD
10007-352 10007-354
SUMO3, human recombinant, BioVision
Proteins and Peptides
>95% Pure active Recombinant human SUMO3.

Typical in vitro concentrations for conjμgate formation is 10-50 µM depending on conditions.

SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation and transcriptional regulation. SUMO functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. Still, unlike ubiquitin which targets proteins for degradation, SUMO is involved in a variety of Cellular processes, for example nuclear transport, transcriptional regulation, apoptosis, and protein stability. The active recombinant SUMO-3 is derived from the precursor pro-SUMO-3 (Accession # NM_006936). Human SUMO-3 shares 47% and 87% identity with SUMO-1 and SUMO-2 respectively. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1, RANBP2, PML, p53, Sp100, HIPK2) but there are also cytosolic substrates (IκBα, GLUT1, GLUT4). SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation, transcriptional regulation, apoptosis and protein stability.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR